Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results
Completed dosing in Phase 1b challenge study of CDI-988 for norovirus prevention and treatment with no serious adverse events reportedPreliminary...
Completed dosing in Phase 1b challenge study of CDI-988 for norovirus prevention and treatment with no serious adverse events reportedPreliminary...
Company to host webcast at 8:00 AM ETNEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO),...
Company leverages patient-derived neurons and AI to support antidepressant choiceKEARNY, N.J. and TEL AVIV, Israel, Nov. 15, 2026 (GLOBE NEWSWIRE)...